Introduction
Incidence of HCC is growing in most countries. 1 In contrast to the most common cancer sites (eg, prostate, breast, and colon) showing successful reductions in the occurrence and deaths, liver cancer, of which HCC represents 80%, shows unfavorable trends; incidence and death rates are increasing at the highest rate of all cancer sites among both men and women. 2 Infection with hepatitis B and/or C virus represents the main risk factor for the development of HCC, contributing to >60% of HCC cases. 3 Other important risk factors for liver cancer include excessive alcohol consumption, nonalcoholic fatty liver disease, obesity, type 2 diabetes mellitus, and rare metabolic disorders. 4, 5 HCC is among the current leading causes of mortality of patients with cirrhosis, the group of patients with the utmost risk of developing HCC. 6 Screening of cirrhotic patients using US with or without alfaphetoprotein determination increases the chance of detecting liver cancer at an early stage when it is more amenable to therapy, 5, 7 including percutaneous treatments (ethanol injection, radiofrequency, and microwaves) as curative therapeutic options. 8, 9 Among ablative therapies, RFA ranks first as diffusion, availability, and physicians' confidence in its therapeutic effectiveness. 10, 11 Recent meta-analyses 12, 13 have suggested that RFA achieved better survival and lower local tumor progression rates than ethanol injection. Moreover, recently published articles [14] [15] [16] [17] have shown that RFA can be offered to patients with HCC nodules up to 2 cm instead of surgical resection, since overall survival and local control of the disease are the same in both the procedures.
Another factor accounting for worldwide spread of RFA is the good safety profile owing to low mortality and major complication rates. 18, 19 However, one of the most feared complications is malignant seeding, ie, development of neoplastic nodules along the needle path, since this is regarded as extrahepatic spread of the disease, thus heralding unfavorable prognosis.
Definition
Percutaneous insertion of a needle into a malignant lesion can entail releasing neoplastic cells along the needle track, so that a metastatic tumor may grow from a few months to several years (in the literature, the range is 6-46 months) after ablation.
Needle track seeding invariably presents with one or multiple rounded nodules along the needle track located within the peritoneum, along the abdominal muscles, which were penetrated by the needle, pleural surface, or in the subcutaneous and cutaneous tissues.
Imaging
At US seeding, implants present as hypoechoic nodules (Figures 1 and 2) , with intralesional vascularization that can be demonstrated by color Doppler, contrast-enhanced US, CT, and MRI, overlapping behavior of intrahepatic tumor. Hypovascular nodules represent a caveat; in these cases, inflammatory processes should be considered. 20 Patient written informed consent including usage of data and images were obtained from the patients for this review.
In case of large implants infiltrating different structures of the abdominal or chest wall, CT and MRI examinations show the extent of the lesion more accurately than does US, which may not image the entire lesion. In the author's opinion, fine needle biopsy (FNB) of the nodule suspicious for malignant implant is mandatory to confirm the diagnosis and plan therapy.
Since the most frequent site of neoplastic implant is the musculocutaneous plane, the area including the needle track of previous biopsy or percutaneous ablative treatment should always be scanned with higher frequency probes (5.0-7.5 MHz) that also have higher resolution and higher sensitivity for color Doppler signals. 20 
Pathogenesis
Several associated risk factors have been identified for neoplastic seeding following RFA for HCC, notably subcapsular tumor location, 21, 22 tumor characteristics, such as poor differentiation grade 22 and intrinsic metastatic property, 23 multiple RFA sessions, 22 history of previous biopsy, 22,24 and patient's immunodepression.
Several mechanisms have been proposed to explain the occurrence of seeding after percutaneous ablative procedures: tumor cells may adhere to an electrode during its retraction; tumor cells may also be carried into the track with a little bleeding; furthermore, increase in intratumoral pressure, which is frequently encountered during RFA, may force cells into the track. 18, 25 According to Snoeren et al, 26 the incidence of viable cells was 17.9% and the incidence of morphologically intact tumor cells was 28.6% when track ablation was not performed. On the contrary, no viable or morphologically intact tumor cells 
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Neoplastic seeding after HCC radiofrequency ablation could be demonstrated when track ablation was applied during RFA procedure.
Frequency
Initially, the report from the Barcelona group of a seeding rate as high as 12.5% in a small series of HCC treated with RFA raised serious concern about the safety of percutaneous thermal ablation. 21 However, it soon became clear that major factors explaining these results were incorrect withdrawal technique (no track ablation had been carried out) and previous diagnostic biopsy. A large survey from Livraghi et al 24 reported a low rate of tumor seeding (0.9%) in 1314 patients and showed that only previous biopsy was significantly associated with tumor seeding. The low risk of seeding after RFA (0-1.1%) has been confirmed in other studies. [27] [28] [29] The systematic review by Stigliano et al 30 confirmed that biopsy prior to RFA increases the risk of seeding since the mean risk for seeding after RFA alone was 1.73% (range 0-5.56%) rising up to 2.5% (range 0-12.5%) if ablation followed diagnostic biopsy.
Although superficial location of the tumor 21, 22 has been advocated as a predisposing factor, a recent series showed that direct subcapsular HCC treated by direct access with radiofrequency (RF) or microwave (MW) did not increase seeding rate. 31 Indeed, the only patient with needle track seeding in this series had a previous diagnostic biopsy.
Treatment
Wide surgical excision is considered as the first-line therapy, provided fascia-to-fascia closure under acceptable tension is feasible. 32 The importance of a wide excision is underlined by the possibility of relapsing seeding after incomplete surgical removal of a neoplastic implant. 33 Other treatments have been proposed alone, such as TACE, 34 MWA and HIFU, 25 and in combination with surgery, such as RFA and PEI. 24 As a rule, the presence of seeding is considered as a contraindication to OLT, but living donor liver transplantation for HCC with full-thickness abdominal wall resection bearing the tumor implant has been recently reported. 35 
Clinical impact
In the meta-analysis of Silva et al, 36 the seeding event had no impact on the patient's survival when the lesion was treated successfully by resection and local ablation. Similarly, in the study of Imamura et al, 37 the cumulative survival rates in HCC patients with neoplastic seeding were 81% at 1 year and 45% at 2 years.
Taking into consideration the relatively low incidence of needle track seeding, the risk of neoplastic implant after thermal ablation could be considered as an acceptable clinical risk.
Prevention
Although surgical sealant infusion 38 has been advocated as a procedure preventing seeding, no robust data exist in the literature. Theoretically, the following two other methods could reduce neoplastic seeding: 1) the coaxial technique as already suggested for biopsy; 39 however, needle track implant after biopsy with such a method has been recently reported, 40 and 2) RFA under laparoscopy as suggested by Santambrogio et al. 41 RF electrodes can be passed through larger laparoscopic sheaths, so avoiding contact of the therapeutic needle with the abdominal wall. However, in this laparoscopic series, seeding occurred after treatment of a large lesion, which required the use of a cluster needle. In addition, it should be underlined that laparoscopic approach is not used as frequently as the percutaneous approach and seems to be limited to those cases when the percutaneous approach to the lesion is deemed very difficult or impossible.
Generally speaking, the biopsy should be avoided especially when a therapeutic option is under consideration for HCC (percutaneous treatment with RF or MW and liver transplantation), relying on good quality cross-sectional imaging. If biopsy is considered mandatory, the number of needle passes should be kept at minimum.
For percutaneous hyperthermic therapeutic procedures, correct needle withdrawal by burning the needle track plays a major role in preventing seeding, even in subcapsular nodules and especially when multiple needle insertions are needed to treat large tumors so as to obtain overlapping ablations or to reposition the needle in a small tumor. In this regard, inexperienced operators should avoid multiple attempts to position the electrode without carrying out track ablation at each withdrawal.
Conclusion
Although needle track seeding after RFA for HCC is traditionally regarded as an ominous complication, its real incidence is acceptably low and can be minimized by reducing biopsy prior to therapeutic interventions and by carrying out needle track ablation after successful thermal ablation of HCC nodules. In addition, thanks to early diagnosis and prompt treatment, development of needle track seeding is not likely to affect the long-term survival of patients.
